Key Points
- Director Musa Tariq sold 116 Guardant Health shares at an average price of $165.88, generating $19,242.08. The transaction was made under a pre-arranged Rule 10b5-1 plan, leaving him with 11,583 shares.
- Guardant Health reported quarterly revenue of $334.98 million, up 44.3% year over year, and an adjusted loss of $0.42 per share—beating analysts’ estimates for both revenue and EPS.
- Analysts maintain a largely bullish view, with a consensus “Moderate Buy” rating and a $190 price target. Institutional investors own approximately 92.6% of the company’s stock.
Guardant Health, Inc. (NASDAQ:GH - Get Free Report) Director Musa Tariq sold 116 shares of the stock in a transaction that occurred on Friday, October 16th. The stock was sold at an average price of $165.88, for a total transaction of $19,242.08. Following the completion of the sale, the director owned 11,583 shares in the company, valued at $1,921,388.04. This represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Musa Tariq also recently made the following trade(s):
- On Wednesday, September 16th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $175.00, for a total transaction of $20,300.00.
- On Monday, August 17th, Musa Tariq sold 116 shares of Guardant Health stock. The shares were sold at an average price of $156.45, for a total transaction of $18,148.20.
Guardant Health Stock Performance
Guardant Health stock opened at $157.88 on Tuesday. The stock has a market cap of $21.19 billion, a P/E ratio of -45.24 and a beta of 1.58. Guardant Health, Inc. has a fifty-two week low of $65.96 and a fifty-two week high of $191.05. The firm's fifty day moving average price is $167.75 and its 200-day moving average price is $139.99.
Guardant Health (NASDAQ:GH - Get Free Report) last posted its quarterly earnings data on Thursday, July 30th. The company reported ($0.42) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.76) by $0.34. The business had revenue of $334.98 million for the quarter, compared to the consensus estimate of $314.23 million. Guardant Health's quarterly revenue was up 44.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.44) EPS. Sell-side analysts predict that Guardant Health, Inc. will post -3.02 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Several analysts have weighed in on GH shares. Citigroup lifted their price target on Guardant Health from $150.00 to $215.00 and gave the company a "buy" rating in a research report on Wednesday, July 8th. Royal Bank Of Canada boosted their price objective on Guardant Health from $185.00 to $200.00 and gave the stock an "outperform" rating in a report on Friday, July 31st. Stephens upped their price objective on shares of Guardant Health from $170.00 to $195.00 and gave the stock an "overweight" rating in a research report on Tuesday, August 4th. Sanford C. Bernstein reaffirmed an "outperform" rating and issued a $210.00 target price on shares of Guardant Health in a research note on Thursday, September 10th. Finally, BTIG Research reaffirmed a "buy" rating and issued a $195.00 target price on shares of Guardant Health in a research note on Wednesday, September 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Guardant Health has a consensus rating of "Moderate Buy" and a consensus price target of $190.00.
View Our Latest Analysis on Guardant Health
Institutional Investors Weigh In On Guardant Health
A number of large investors have recently added to or reduced their stakes in the company. ABS Investment Management LLC purchased a new position in shares of Guardant Health in the 2nd quarter worth about $345,069,000. The Manufacturers Life Insurance Company purchased a new position in shares of Guardant Health during the 2nd quarter valued at about $208,592,000. William Blair Investment Management LLC purchased a new position in shares of Guardant Health during the 2nd quarter valued at about $196,737,000. First Light Asset Management LLC lifted its position in Guardant Health by 57.5% in the 2nd quarter. First Light Asset Management LLC now owns 441,586 shares of the company's stock worth $66,251,000 after buying an additional 161,287 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Guardant Health by 159.9% in the 2nd quarter. Handelsbanken Fonder AB now owns 301,041 shares of the company's stock worth $45,165,000 after buying an additional 185,200 shares during the last quarter. Hedge funds and other institutional investors own 92.60% of the company's stock.
About Guardant Health
(
Get Free Report)
Guardant Health, Inc (NASDAQ:GH) is a precision oncology company that develops blood-based tests and data solutions designed to help detect cancer, guide treatment decisions and monitor patients over time. Its technologies analyze circulating tumor DNA and other molecular information from blood samples, supporting more accessible and less invasive alternatives to some tissue-based testing approaches.
The company's products include Guardant360, which helps identify genomic alterations in advanced cancers and may inform targeted treatment selection; Guardant360 Response, designed to assess a patient's response to therapy; and Guardant Reveal, which is used to detect minimal residual disease and recurrence risk in certain cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
